Pediatric Ulcerative Colitis Treatment With SIMPONI®
While individual results may vary, SIMPONI® was established in a clinical study to:
Pediatric patients knew they were on SIMPONI® for the entire study.
AT 6 WEEKS
More than 3 in 10 patients were in clinical remission at Week 6.
SIMPONI® (N=21/66)
The primary endpoint was clinical remission at Week 6.
AT 6 WEEKS
Over 5 out of 10 pediatric patients receiving SIMPONI® had improvement in their UC symptoms by Week 6 of treatment.
SIMPONI® (N=38/66)
Clinical response at Week 6 was a secondary endpoint
AT 54 WEEKS
Of the patients who were in remission at 6 weeks, over 5 out of 10 maintained remission at 1 year.
SIMPONI® (N=12/21)
Maintenance of clinical remission at Week 54 was a secondary endpoint
Clinical remission at 54 weeks among patients who responded to SIMPONI® at Week 6, secondary endpoint: 34% (N=13/38) of patients receiving SIMPONI®
How Does SIMPONI® Work?
Before starting a new medication, it's important to know what it is and how it works. Here's a closer look at SIMPONI®.
SIMPONI® is a TNF blocker biologic medicine
It targets and blocks a protein called TNF-alpha (tumor necrosis factor-alpha)
SIMPONI® specifically targets excess TNF-alpha, helping to block an underlying cause of the symptoms of UC. SIMPONI® can bind with 2 forms of TNF-alpha, and at more than 1 location.
SIMPONI® targets, binds with, and blocks excess TNF-alpha, helping to control inflammation.
SIMPONI® targets, binds with, and blocks excess TNF-alpha, helping to control inflammation

Blocking too much TNF-alpha can make it harder for your body to fight infections. See your doctor regularly. Tell him or her if you have side effects.
SIMPONI® is not for everyone. Only your doctor can decide if SIMPONI® is right for you.